IDH1 and central nervous system cancer: Gliomas that harbour an IDH1/2 mutation (IDH-mutant astrocytoma and IDH-mutant and 1p19q-codeleted oligodendroglioma) result in improved patient outcomes as compared to the IDH-wildtype glioblastoma.